Transgene Biotek Ltd — Results, 22-05-2025: Integrated Filing

Transgene Biotek has announced a board meeting on which it approved the audited financial results for the quarter and half-year. The company recorded total income of ₹104.42 Lakhs for the year, with a net loss of ₹67.61 Lakhs, similar to the previous year. Finance costs rose significantly to ₹24.30 Lakhs. The company strengthened its liquidity by raising secured debt and cleared dues to BIRAC. Oral insulin clinical studies are progressing well without side effects. The company faces a penalty of ₹203.02 Cr from the Enforcement Directorate related to a past GDR issue; this is under appeal with a hearing scheduled. Subsidiary Transgene Biotek HK Ltd remains non-operational.